Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 128Lung Neoplasms 49Breast Neoplasms 24Head and Neck Neoplasms 21Adenocarcinoma of Lung 18Brain Neoplasms 15Neoplasms 14Adenocarcinoma, Bronchiolo-Alveolar 11Squamous Cell Carcinoma of Head and Neck 10Glioblastoma 9Esophageal Neoplasms 9Colorectal Neoplasms 9Rectal Neoplasms 7Prostatic Neoplasms 7Neoplasm Metastasis 7NSCLC 7Gliosarcoma 7Colonic Neoplasms 7Adenocarcinoma Of Esophagus 7Ovarian Neoplasms 5Esophageal Squamous Cell Carcinoma 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Renal Cell 4Carcinoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Skin Neoplasms 3Respiratory Tract Diseases 3Kidney Neoplasms 3

Interventions

Amifostine 19Cisplatin 15Radiotherapy 13Etoposide 10Cyclophosphamide 9Carboplatin 8Paclitaxel 7Filgrastim 7Drug Therapy 5Cytarabine 5apatinib 4sodium thiosulfate 3Methylprednisolone 3Methotrexate 3Gemcitabine 3Docetaxel 3sargramostim 2pegfilgrastim 2etoposide phosphate 2camrelizumab 2Vincristine 2Pyridoxine 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mitoxantrone 2Melphalan 2Irinotecan 2Ifosfamide 2Fibroblast Growth Factor 7 2Epoetin Alfa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Drug-Related Side Effects and Adverse Reactions × Gefitinib × Clear all
NCT01965275 2017-05-08

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Anhui Medical University

Phase 2 Unknown
20 enrolled

Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡